Syndax
  • Home
  • About Us
    • Back
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Vision, Mission, and Values
  • Patients & Caregivers
  • Pipeline
    • Back
    • Pipeline
    • Entinostat
    • SNDX-6352
    • SNDX-5613
    • Clinical Trials
    • Publications
    • Compassionate Use
  • Investors
  • Collaboration
  • Career Opportunities
  • Contact Us
Syndax
Contact Us
  • About
  • Patients & Caregivers
  • Pipeline
  • Investors
  • Collaboration
  • Join Us

Determined to realize a future in which people with cancer live longer and better than ever before.


  • What is entinostat?
  • What is SNDX-6352?
  • What is SNDX-5613?
  • What clinical trials is Syndax currently conducting?
  • Who is on the leadership team at Syndax?
  • Where can I see your product pipeline?
  • What is the vision of Syndax?
  • Is Syndax hiring?
  • How can my organization collaborate with Syndax?
Pipeline
Leadership
Clinical Trials
Publications

12.10.19

Syndax Pharmaceuticals Announces Plans to Commence Phase 2 Expansion Cohort of SNDX-6352 for the Treatment of Chronic Graft Versus Host Disease

12.09.19

Syndax Announces Preclinical Results Supporting Development of its Portfolio of Menin inhibitors In Mixed Lineage Leukemias

11.07.19

Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update

11.06.19

Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias

© 2019 Syndax | Terms of Use | Privacy Policy | Site Map
  • About Us
  • Pipeline
  • Investors
  • Collaboration
  • Career Opportunities